Report spotlights how imposing price controls and government regulations hamper drug approvals and slow competition.
Taxpayers and Patients Win First Round on 340B Drug Discount Rule
On January 1, 2018, hospitals will begin to receive lower government reimbursements for drugs purchased under the 340B program.
New CMS Rule Will Help Reduce Drug Costs
On Wednesday, November 1, 2017, the Centers for Medicare and Medicaid Services (CMS) issued a new rule that will lower costs to taxpayers and Medicare beneficiaries for certain outpatient pharmaceuticals purchased under the 340B drug discount program. According to CMS Administrator Seema Verma, “As part of the President’s priority to lower the cost of prescription […]
How the 340B Drug Discount Program is Increasing Cancer Costs
Cancer care costs are rising, and the 340B outpatient drug discount program is needlessly contributing to the increase.
Judge Tells Federal Agency to Obey the Law for Drug Discount Program
Taxpayers and consumers pay for misuse of the 340B program through higher insurance premiums, increased drug prices and taxes.
More Proof the 340B Program Needs Reform
A July 6, 2015 GAO report confirms that reform of the 340B program is necessary.
340B Drug Discount Program Finally Gets a Congressional Hearing
House Energy and Commerce Subcommittee on Health holds first hearing on the 340B drug discount program since 2005.
When Will Congress Fix the 340B Drug Discount Program?
The 340B drug discount program to help uninsured, low-income individuals obtain prescription drugs has strayed from its mission.
The Federal 340B Discount Drug Program Needs Reform
The federal 340B drug discount program is in need of congressional oversight and reform.
What is the 340B Program and Why You Need to Care
Problems in the 340B drug discount program are growing and costs are increasing due as more entities participate in the program.